Silexion Therapeutics Corp已正式获得以色列卫生部批准,将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步,为评估其在治疗这一难治性癌症方面的潜力铺平了道路。
Silexion Therapeutics Corp已正式获得以色列卫生部批准,将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步,为评估其在治疗这一难治性癌症方面的潜力铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.